Herantis’s ‘Elegant’ Approach In Parkinson’s

episode

Citeline Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Your partner wants profit. You want freedom. Now what? 22 min · 16 Sep 2026 · The Optometry Success Podcast

Board of County Supervisors Meeting - Work Session - Sep 15, 2026 3h 17m · 15 Sep 2026 · Prince William County Board of Supervisors

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

NPR News: 09-13-2026 6PM EDT 4 min · 13 Sep 2026 · NPR News Now

Report any issue

Source

Recorded21 Jan 2026

Publisherfeeds.soundcloud.com ↗

Handlerec:15439381

Show notes

Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related